The invention features a oligonucleotide of formula (I) or pharmaceutically acceptable salts,
or prodrugs thereof (I) which arc capablc of inducing an anti-viral or an antibactcrial …

The present invention provides an oligonucleotide which is capable of activating RIG-I and
inducing an anti-viral, in particular, an IFN, response in cells expressing RIG-I. The present …

US10059943B2 - RIG-I ligands and methods for producing them - Google Patents US10059943B2
- RIG-I ligands and methods for producing them - Google Patents RIG-I ligands and methods …

Oligonucleotides bearing free, uncapped 5′ phosphate group (s) are recognized by RIG-I,
leading to the induction of type I IFN, IL-18 and IL-1β production. Bacterial RNA also induces …

US10072262B2 - RIG-I ligands and methods for producing them - Google Patents
US10072262B2 - RIG-I ligands and methods for producing them - Google Patents RIG-I …

BACKGROUND 0003 Oligonucleotide 5'-triphosphates (ONTPs) are not commercially
available; still they find a great number of important biochemical applications: DNAONTPs …

US8987221B2 - Potentiation of autoimmune and inflammatory disease treatments by
immune regulatory oligonucleotide (IRO) antagonists of TLR7 and TLR9 - Google Patents …

The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of
TLRs and methods of use thereof. These IROs have unique sequences that inhibit or …

The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of
TLRs and methods of use thereof. These IROs have unique sequences that inhibit or …

The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of
TLRs and methods of use thereof. These IROs have unique sequences that inhibit or …